Received Jun 15, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 553E2 | — |
Rash; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of rash in a female patient who received HBV (Engerix B) suspension for injection in pre-filled syringe (batch number 553E2 with expiry date 16-JAN-2028) for prophylaxis. Previously administered products included Engerix B with an associated reaction of no adverse event (received 1st dose on an unknown date, no side effects). On an unknown date, the patient received the 2nd dose of Engerix B. On an unknown date, less than a week after receiving Engerix B, the patient experienced rash (Verbatim: Rash). The outcome of the rash was unknown. It was unknown if the reporter considered the rash to be related to Engerix B and Engerix B Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 11-JUN-2026 The reporter stated that one of our employees that did the hepatitis series treated through the first one, with no side effects; got the second one and within a day or two, ended up having a rash. He/she knew that could be a side effect of hepatitis B but this person that came across, it never had this before and they were wondering if there it was batch related. The reporter had any reports of specific batches that were causing more rashes on employees in second rounds or Third rounds.